← All events

Biotech Wednesday ‘Next frontiers in cancer vaccines’

Samen met HollandBIO


HollandBIO is joining forces again with Oncode Institute to bring you a new Biotech Wednesday! With this year’s theme: ‘Next frontiers in cancer vaccines – Valorization of scientific excellence’

12:15 Walk-in, registration and lunch
13:00 Word of welcome
13:10 Sjoerd van der Burg, Professor of Cancer Immunology & Therapy
13:40 Gerben Moolhuizen, CEO ISA Pharmaceuticals
14:05 Ronald Plasterk, CEO Frame Therapeutics
14:30 Coffee and tea break
15:00 Carl Figdor, Professor of Immunology
15:25 Erik Manting, CEO Immunicum AB
15:50 Panel discussion
16:15 Networking drinks
17:30 End

Practical information
Date: November 24, 2021
Time: 12:15 pm – 17:30 pm
Venue: Pakhuis de Zwijger, Piet Heinkade 179, Amsterdam

Registration is now open. You can register here.

Who can join Biotech Wednesday
Biotech Wednesday is open to all interested organizations and free of charge (max. 3 delegates per organization) HollandBIO members and academia have priority.

Please note
Registration does not guarantee a seat at the event yet. Ongoing COVID-19 restrictions may force us to limit the amount of registrants. To be able to access the event you need to be fully vaccinated or show a negative test result within 24 hours before the event takes place or show a corona recovery proof (within a half year before the event). HollandBIO follows the guidelines provided by the Dutch government and the National Institute for Public Health and the Environment (RIVM).

About this Biotech Wednesday
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. In this meeting pioneering industry and academics will outline the cancer vaccine therapy and immunotherapy with a focus on novel vaccine platforms and antigens, underscoring the renewed optimism that has risen during pandemic. The field of therapeutic cancer vaccines is fast evolving, and while the diverse platforms or targets are currently being evaluated, valorization of this yet-to-be established innovations stays challenging.

Powered by

Kaart wordt geladen...